Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Adaptive Phage Therapeutics, Inc.
With
United States Department of Defense
This study will evaluate the safety and efficacy of bacteriophage therapy in patients with urinary tract infection (UTI). Patients to be enrolled will have urinary tract infections due to E. coli and K. pneumoniae. This will include asymptomatic patients with neurogenic bladder and symptomatic patients with complicated urinary tract infections who are at risk of UTI recurrence. Patients will be followed for bacterial clearance or recurrence of urinary tract infection.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males or females ≥18 years of age.
Female patients of childbearing potential.
Male patients must agree not to donate sperm up for one month.
English-speaking.
You may not be if
Stage 4 or greater chronic kidney disease (CKD).
Abnormal liver function tests \>3×upper limit of normal (ULN).
Other conditions which could confound study results.
Body mass index of \> 40 or weight less than 50 kg.
